Earnings Releases·Nov 5, 2026, 7:05 AM ET

Iovance Biotherapeutics — Third Quarter 2026 Earnings Summary

Total product revenue reached ~$122 million, an ~80% year-over-year increase and ~22% sequential rise, while net loss narrowed significantly to $22.271 million from $91.253 million in the prior year period.
Gross margin expanded to ~60% and R&D expenses decreased ~16% sequentially, with cash and investments totaling $376.320 million to fund operations well into 2029.
The company remains on track to achieve full-year 2026 revenue guidance of $410 to $420 million, supported by over 1,000 commercially treated patients and an ATC network expanding to 110 centers by year-end.
Pipeline progress includes a 24.6% ORR in the IOV-LUN-202 lung cancer trial with an sBLA planned for 2027, alongside FDA Fast Track Designations for lifileucel in mNSCLC, UPS, and DDLPS.
Global expansion efforts are advancing with Marketing Authorization Applications under review in the UK and Switzerland, targeting potential approvals in Q1 2027.